

# Libero Italo Giannola

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4726214/publications.pdf>

Version: 2024-02-01

39  
papers

1,072  
citations

430754

18  
h-index

414303

32  
g-index

39  
all docs

39  
docs citations

39  
times ranked

1218  
citing authors

#	ARTICLE	IF	CITATIONS
1	Solid and Semisolid Innovative Formulations Containing Miconazole-Loaded Solid Lipid Microparticles to Promote Drug Entrapment into the Buccal Mucosa. <i>Pharmaceutics</i> , 2021, 13, 1361.	2.0	10
2	Comparative Study of the Effects Exerted by N-Valproyl-L-Phenylalanine and N-valproyl-L-tryptophan on CA1 Hippocampal Epileptiform Activity in Rat. <i>Current Pharmaceutical Design</i> , 2018, 24, 1849-1858.	0.9	5
3	Small endogenous molecules as moiety to improve targeting of CNS drugs. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 93-107.	2.4	10
4	Assessment of in vivo organ-uptake and in silico prediction of CYP mediated metabolism of DA-Phen, a new dopaminergic agent. <i>Computational Biology and Chemistry</i> , 2017, 71, 63-69.	1.1	0
5	<i>In situ</i> delivery of corticosteroids for treatment of oral diseases. <i>Therapeutic Delivery</i> , 2017, 8, 899-914.	1.2	7
6	Effects of DA-Phen, a dopamine-aminoacidic conjugate, on alcohol intake and forced abstinence. <i>Behavioural Brain Research</i> , 2016, 310, 109-118.	1.2	11
7	Potential transbuccal delivery of <i>l</i> -DOPA methylester prodrug: stability in the environment of the oral cavity and ability to cross the mucosal tissue. <i>Drug Delivery</i> , 2016, 23, 2355-2362.	2.5	9
8	Studies on a new potential dopaminergic agent: <i>in vitro</i> BBB permeability, <i>in vivo</i> behavioural effects and molecular docking evaluation. <i>Journal of Drug Targeting</i> , 2015, 23, 910-925.	2.1	10
9	Alain delivery on buccal mucosa: <i>ex vivo</i> studies and design of a new locoregional dosing system. <i>Drug Development and Industrial Pharmacy</i> , 2015, 41, 1541-1547.	0.9	29
10	Acetaldehyde self-administration by a two-bottle choice paradigm: Consequences on emotional reactivity, spatial learning, and memory. <i>Alcohol</i> , 2015, 49, 139-148.	0.8	31
11	Buccal drug delivery: what's new and what does the future hold?. <i>Therapeutic Delivery</i> , 2014, 5, 965-968.	1.2	2
12	Controlled delivery of naltrexone by an intraoral device: In vivo study on human subjects. <i>International Journal of Pharmaceutics</i> , 2013, 452, 128-134.	2.6	15
13	Physical methods to promote drug delivery on mucosal tissues of the oral cavity. <i>Expert Opinion on Drug Delivery</i> , 2013, 10, 1449-1462.	2.4	22
14	Buccal Delivery of Methimazole as an Alternative Means for Improvement of Drug Bioavailability: Permeation Studies and Matrix System Design. <i>Current Pharmaceutical Design</i> , 2012, 18, 5405-5410.	0.9	9
15	Medium-Term Culture of Primary Oral Squamous Cell Carcinoma in a Three- Dimensional Model: Effects on Cell Survival Following Topical 5-Fluororacile Delivery by Drug-Loaded Matrix Tablets. <i>Current Pharmaceutical Design</i> , 2012, 18, 5411-5420.	0.9	8
16	Inhibitory effects of N-valproyl-L-tryptophan on high potassium, low calcium and low magnesium-induced CA1 hippocampal epileptiform bursting activity in rat brain slices. <i>Journal of Neural Transmission</i> , 2012, 119, 1249-1259.	1.4	11
17	Oral local drug delivery and new perspectives in oral drug formulation. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2012, 114, e25-e34.	0.2	87
18	New prospective in treatment of Parkinson's disease: Studies on permeation of ropinirole through buccal mucosa. <i>International Journal of Pharmaceutics</i> , 2012, 429, 78-83.	2.6	39

#	ARTICLE	IF	CITATIONS
19	N-Valproyl-L-Tryptophan for CNS-Targeting: Synthesis, Characterization and Efficacy In Vitro Studies of a New Potential Antiepileptic Drug. <i>Medicinal Chemistry</i> , 2011, 7, 9-17.	0.7	7
20	Human Buccal Mucosa as an Innovative Site of Drug Delivery. <i>Current Pharmaceutical Design</i> , 2010, 16, 641-652.	0.9	66
21	5-Fluorouracil Buccal Tablets for Locoregional Chemotherapy of Oral Squamous Cell Carcinoma: Formulation, Drug Release and Histological Effects on Reconstituted Human Oral Epithelium and Porcine Buccal Mucosa. <i>Current Drug Delivery</i> , 2010, 7, 109-117.	0.8	25
22	Bioavailability in vivo of naltrexone following transbuccal administration by an electronically-controlled intraoral device: A trial on pigs. <i>Journal of Controlled Release</i> , 2010, 145, 214-220.	4.8	39
23	New Prospectives in the Delivery of Galantamine for Elderly Patients Using the IntelliDrug Intraoral Device: In Vivo Animal Studies. <i>Current Pharmaceutical Design</i> , 2010, 16, 653-659.	0.9	21
24	Potential dopamine prodrug-loaded liposomes: preparation, characterization, and in vitro stability studies. <i>Journal of Liposome Research</i> , 2010, 20, 250-257.	1.5	18
25	Drug delivery from the oral cavity: focus on a novel mechatronic delivery device. <i>Drug Discovery Today</i> , 2008, 13, 247-253.	3.2	80
26	Evaluation of galantamine transbuccal absorption by reconstituted human oral epithelium and porcine tissue as buccal mucosa models: Part I. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 70, 869-873.	2.0	30
27	Ocular Gelling Microspheres: <i>In Vitro</i> Precorneal Retention Time and Drug Permeation Through Reconstituted Corneal Epithelium. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2008, 24, 186-196.	0.6	17
28	Diffusion of naltrexone across reconstituted human oral epithelium and histomorphological features. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2007, 65, 238-246.	2.0	42
29	Release of naltrexone on buccal mucosa: Permeation studies, histological aspects and matrix system design. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2007, 67, 425-433.	2.0	78
30	Lipid Phase Transition in Saccharide-Coated Cholate-Containing Liposomes: A Coupling to the Surrounding Matrix. <i>Langmuir</i> , 2005, 21, 4108-4116.	1.6	19
31	Effects of gamma-irradiation on trehalose-hydroxyethylcellulose microspheres loaded with vancomycin. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2005, 59, 139-146.	2.0	18
32	A new delivery system of clobetasol-17-propionate (lipid-loaded microspheres 0.025%) compared with a conventional formulation (lipophilic ointment in a hydrophilic phase 0.025%) in topical treatment of atrophic/erosive oral lichen planus. A Phase IV, randomized, observer-blinded, parallel group clinical trial. <i>British Journal of Dermatology</i> , 2004, 150, 984-990.	1.4	60
33	Trehalose-hydroxyethylcellulose microspheres containing vancomycin for topical drug delivery. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2001, 52, 83-89.	2.0	24
34	Functional feature of a novel model of blood brain barrier: studies on permeation of test compounds. <i>Journal of Controlled Release</i> , 2001, 76, 139-147.	4.8	59
35	Neurons and ECM regulate occludin localization in brain endothelial cells. <i>NeuroReport</i> , 2000, 11, 1081-1084.	0.6	111
36	Synthesis of polymeric derivatives of isoniazid: Characterization and in vitro release from a water-soluble adduct with polysuccinimide. <i>Chemical and Pharmaceutical Bulletin</i> , 1989, 37, 1106-1108.	0.6	10

#	ARTICLE	IF	CITATIONS
37	Synthesis of macromolecular prodrugs of procaine, histamine and isoniazid.. Chemical and Pharmaceutical Bulletin, 1989, 37, 2245-2247.	0.6	14
38	High-performance liquid chromatography with fluorimetric detection in biological tissues of the 4-bromomethyl-7-methoxycoumarin ester derivative of 5-pyrrolidone-2-carboxylic acid. Biomedical Applications, 1985, 344, 325-331.	1.7	8
39	Synthesis of 5 <i>H</i> -[1,2]-benzothiazolo[2,3- <i>a</i> ]quinazolin-5-one. Journal of Heterocyclic Chemistry, 1975, 12, 1077-1078.	1.4	11